Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus curvatus WiKim38
- Development stage
- Preclinical
- Lead developer
- Hankook Korus Pharm
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
HKP301 is a probiotic health functional food product being developed by Hankook Korus Pharm for the prevention of bone diseases, such as osteoporosis. The active ingredient is Lactobacillus curvatus WiKim38, a probiotic bacterial strain originally isolated from kimchi. The product's mechanism of action involves the inhibition of RANKL-induced osteoclast differentiation. Research has demonstrated that the cell-free culture supernatant of L. curvatus WiKim38 decreases the activation of the TRAF6/NF-κB/MAPKs signaling axis and reduces the expression of genes associated with osteoclastogenesis. In preclinical studies using ovariectomized mice, a model for postmenopausal osteoporosis, administration of the strain's culture supernatant was shown to increase bone volume and bone mineral density.
- Other names
- L. curvatus WiKim38
02
Targets
NF-κBMEKTRAF6RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)
Beyond the preview
Go deeper on Lactobacillus curvatus WiKim38.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus curvatus WiKim38.